Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

Hematol J. 2003;4(6):379-98.


These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1. Diagnostic criteria. 2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies.

Publication types

  • Guideline
  • Practice Guideline
  • Review

MeSH terms

  • Anemia / etiology
  • Anemia / therapy
  • Antineoplastic Agents / standards
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Diseases / etiology
  • Bone Diseases / therapy
  • Diagnosis, Differential
  • Humans
  • Kidney Diseases / etiology
  • Kidney Diseases / therapy
  • Multiple Myeloma / complications
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / mortality
  • Multiple Myeloma / therapy*
  • Quality Assurance, Health Care
  • Stem Cell Transplantation / standards
  • Survival Analysis


  • Antineoplastic Agents